Navigation Links
Despite Generic Erosion of Key Brands, the Hospital-Acquired Gram Negative Infections Drug Market Will Increase by $1 Billion from 2008 to 2018
Date:6/16/2009

Uptake of Novel Agents from Novexel, Johnson & Johnson and Wyeth Will Drive Growth, According to a New Report from Decision Resources

WALTHAM, Mass., June 16 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite generic erosion of key brands, the hospital-acquired gram-negative infections drug market will increase by $1 billion from 2008 to 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Gram Negative Infections finds that the introduction and uptake of next-generation cephalosporins, carbapenems, quinolones, and beta-lactam/beta-lactamase inhibitors, will be a significant driver of market growth through 2018. Among these emerging therapies, Novexel's NXL-104/ceftazidime, a novel beta-lactam/beta-lactamase inhibitor agent, is positioned to offer the most significant advance in the treatment of hospital-acquired gram-negative infections and will earn more than $250 million in sales in 2018. Additionally, the continued uptake of two recent market entrants -- Johnson & Johnson's Doribax and, to a lesser extent, Wyeth's Tygacil -- will also drive the market. Although these three agents and several other emerging therapies will drive market growth, generic erosion of key brands will temper overall market sales through 2018, according to the report.

Generic erosion of top branded products such as piperacillin/tazobactam (Wyeth's Zosyn/Tazocin), imipenem/cilastatin (Merck's Primaxin/Tienam), meropenem (Cubist Pharmaceuticals/AstraZeneca's Merrem/Meronem) and levofloxacin (Johnson & Johnson's Levaquin, Sanofi-Aventis's Tavanic and Daiichi Sankyo's Cravit) will have the greatest impact on the market. In 2008, these four products accounted for approximately 50 percent of the hospital-acquired gram-negative infections market. The report forecasts that, in 2018, generic erosion will reduce the combined sales of these agents to approximately 25 percent of the market.

The report also finds that drug development for gram-negative infections has been slow and overshadowed by interest and investment in developing novel therapies for the more lucrative market of hospital-acquired infections due to gram-positive pathogens, namely, methicillin-resistant Staphylococcus aureus (MRSA). However, as competition increases and opportunities decline in the market for hospital-acquired infections due to MRSA, the hospital-acquired gram-negative infections market segment is ripe with attractive drug development opportunities.

"Competition between agents is relatively low in the hospital-acquired gram-negative infections market when compared with the market for hospital-acquired infections due to gram-positive pathogens," said Decision Resources Analyst Hemali Patel, Ph.D. "Minimal competition in the late-stage pipeline and high unmet need will allow novel agents with clearly demonstrated efficacy against key gram-negative pathogens to command a high price and favorable formulary position -- two key attributes that underlie commercial success in this market."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                              Decision Resources, Inc.
    Christopher Comfort                             Elizabeth Marshall
    781-296-2597                                    781-296-2563
    ccomfort@dresources.com                         emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Despite overeating, morbidly obese mice gain protection against diabetes
2. Despite grumbling, most Americans say they are happy at work
3. Most patients who have male-to-female sex-change surgery are happy, despite complications
4. Cataract Surgery: A Bargain, Despite the Price
5. UGA study: Youth exposed to smokeless tobacco ads despite settlement
6. Despite Advances in the Accuracy of CT Colonography in Detecting Polyps, Digestive Health Experts Urge Patients to Consider Risks and Realities
7. Plastic Surgery Complications and Deaths are Rare, Despite Highly Publicized Death of Donda West
8. A Full and Long Life, Despite Diabetes
9. Enrollment Growth Slows at U.S. Nursing Colleges and Universities in 2007 Despite Calls for More Registered Nurses
10. Research finds allergic children exposed to peanuts at younger ages despite recommendations to avoid
11. Miscarriage myths persist despite prevalence of medical information
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... West Palm Beach, FL (PRWEB) , ... April 21, 2017 , ... The staff at ... FACS , will be taking part in the 2017 London Marathon. Set to take place ... variety of charitable organizations. This year, Dr. Schwartz will run as part of team EMPOWER, ...
(Date:4/21/2017)... , ... April 21, 2017 , ... Brady ... that its B-595 and B-7569 vinyl label materials received certification ... warning labels are tested to remain intact and legible, for use on chemical drums ...
(Date:4/21/2017)... , ... April 21, 2017 , ... The Patient Advocacy ... Health System, with the 2017 Ruth Ravich Patient Advocacy Award in recognition ... advocates. DeVaro was honored with the award at The Beryl Institute’s annual Patient ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... campaign, AWARE: A Week of Addiction and Recovery Education, from April 24 to ... and preventing substance use disorders. , The mission of AWARE is to ...
(Date:4/21/2017)... ... 21, 2017 , ... Metrasens is honoured to have won ... most prestigious award for business success. The company has been recognized for ... grown by a total of 400% over the last six years. , Metrasens ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... DIEGO , April 19, 2017  Sorrento ... an antibody-centric, clinical-stage biopharmaceutical company developing new treatments ... announced the closing of its previously announced underwritten ... stock at a public offering price of $2.00 ... and estimated offering expenses payable by Sorrento.  The ...
(Date:4/19/2017)... HANOVER, N.J. , April 19, 2017 /PRNewswire/ ... conducted by the National Heart, Lung, and Blood ... (NIH) demonstrating that 58% of patients with treatment-naïve ... six months when treated with eltrombopag at the ... 1 . The study evaluated three sequential treatment ...
(Date:4/18/2017)... Cogentix Medical, Inc. (NASDAQ: CGNT), a global medical device ... markets with innovative and proprietary products, will release financial ... after the market close on Tuesday, May 2, 2017. ... call and webcast to discuss its financial results the ... p.m. Eastern Time (3:30 p.m. Central Time). Darin ...
Breaking Medicine Technology: